# A CR-UK Phase I Trial of LY3143921

> **NCT03096054** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Research UK** · enrollment: 69 (actual)

## Conditions studied

- A. Colorectal Cancer
- B. High Grade Serous Ovarian Cancer
- C. Non Small-cell Lung Cancer (squamous Cell Variant)
- D. Squamous Carcinoma of the Oesophagus
- E. Squamous Carcinoma of the Head and Neck (HPV Negative)
- F. Urothelial Cancer
- G. Breast Cancer (triple Negative Type)
- H. Pancreatic Cancer

## Interventions

- **DRUG:** LY3143921 hydrate

## Key facts

- **NCT ID:** NCT03096054
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-21
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03096054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03096054, "A CR-UK Phase I Trial of LY3143921". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03096054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*